Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Source:
    The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2009 Jun 12 5, 589 (589-97)
  • Additional Information
    • Author(s):
      O'Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, Wu R, Makuch RW
    • Contact Information:
      Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA. [email protected]
    • Review Group(s):
      Cochrane Tobacco Addiction Group Trials in the Group's Specialized Register
    • Language:
      English
    • Publication Type:
      Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
    • Record Status:
      This record is updated this issue.
    • Abstract:
      The opiate antagonist naltrexone (Ntx) has demonstrated efficacy in the treatment of alcohol dependence and as a component of treatment to reduce heavy drinking. At present, there are no published dose-ranging clinical trials of the oral preparation for treatment of problem drinking. The present study evaluated the effects of Ntx on alcohol use among the subset of hazardous drinkers (n=102) who participated in a placebo-controlled, dose-ranging trial of oral Ntx (25-mg, 50-mg and 100-mg doses) combined with open-label transdermal nicotine patch for enhancing smoking cessation. On the primary outcome--no hazardous drinking (drinking that exceeded weekly or daily limits) during treatment--25 mg and 50 mg Ntx were superior to placebo (each p
    • Medical Subject Headings (MeSH):
      Adult
      Female
      Humans
      Male
      Middle Aged
      Alcohol Drinking/psychology
      Alcoholism/drug therapy
      Alcoholism/psychology
      Dose-Response Relationship, Drug
      Smoking/psychology
      Alcohol Drinking/*drug therapy
      Naltrexone/*administration & dosage
      Smoking/*drug therapy
      Smoking Cessation/*methods
    • Source:
      This document should be cited as: O'Malley SS Krishnan-Sarin S McKee SA Leeman RF Cooney NL Meandzija B Wu R Makuch RW. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation 2009 Jun (The Cochrane Controlled Trials Register (CCTR/CENTRAL). DOI: 10.1017/S146114570800936X. Oxford: Update Software. Updated quarterly.
    • Accession Number:
      CN-00729386
  • Citations
    • ABNT:
      O’MALLEY SS et al. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), [s. l.], v. 12, n. 5, p. 589–597, 2009. DOI 10.1017/S146114570800936X. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=cgh&AN=CN-00729386. Acesso em: 23 out. 2020.
    • AMA:
      O’Malley SS, Krishnan-Sarin S, McKee SA, et al. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2009;12(5):589-597. doi:10.1017/S146114570800936X
    • APA:
      O’Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, Wu R, & Makuch RW. (2009). Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), 12(5), 589–597. https://doi.org/10.1017/S146114570800936X
    • Chicago/Turabian: Author-Date:
      O’Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, Wu R, and Makuch RW. 2009. “Dose-Dependent Reduction of Hazardous Alcohol Use in a Placebo-Controlled Trial of Naltrexone for Smoking Cessation.” The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 12 (5): 589–97. doi:10.1017/S146114570800936X.
    • Harvard:
      O’Malley SS et al. (2009) ‘Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation’, The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), 12(5), pp. 589–597. doi: 10.1017/S146114570800936X.
    • Harvard: Australian:
      O’Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, Wu R & Makuch RW 2009, ‘Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation’, The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), vol. 12, no. 5, pp. 589–597, viewed 23 October 2020, .
    • MLA:
      O’Malley SS, et al. “Dose-Dependent Reduction of Hazardous Alcohol Use in a Placebo-Controlled Trial of Naltrexone for Smoking Cessation.” The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), vol. 12, no. 5, June 2009, pp. 589–597. EBSCOhost, doi:10.1017/S146114570800936X.
    • Chicago/Turabian: Humanities:
      O’Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, Wu R, and Makuch RW. “Dose-Dependent Reduction of Hazardous Alcohol Use in a Placebo-Controlled Trial of Naltrexone for Smoking Cessation.” The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 12, no. 5 (June 1, 2009): 589–97. doi:10.1017/S146114570800936X.
    • Vancouver/ICMJE:
      O’Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, et al. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) [Internet]. 2009 Jun 1 [cited 2020 Oct 23];12(5):589–97. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=cgh&AN=CN-00729386